Breast cancer among HIV infected individuals from the ONCOVIH study, in France: therapeutic implications

Eur J Cancer. 2012 Dec;48(18):3335-41. doi: 10.1016/j.ejca.2012.05.019. Epub 2012 Jul 3.

Abstract

Background: The cross-sectional ONCOVIH study prospectively enrolled HIV-infected adults and children with newly diagnosed malignancies in France in 2006.

Method: We report the characteristics HIV-infected patients with breast cancer from the ONCOVIH study. Standardised questionnaires included characteristics of HIV infection and malignancy. Survival was estimated using Kaplan-Meier estimates.

Results: Overall, 21 patients with breast cancer (two men and 19 women) were included with a median age of 43.8 years, (range: 30.1-65.5). At time of tumour diagnosis, the median CD4 count was 384/mm(3) (range: 180-1039) the median duration of known seropositivity 7.7 years (range: 0-20.3); 14 patients were under combined antiretroviral therapy for a median duration of 5.7 years (range: 1.1-10.6), of whom 11 had a controlled viral load (<500 copies/mL). The median tumour size was 1.8 cm (range: 1.0-7.0). In women, 17 (89.5%) had invasive ductal carcinoma, 17 (89.5%) with HER2 negative receptors, 8 (42.1%) with ER+ expression, and 7 (36.8%) with PR+ expression. A majority of women received chemotherapy (73.7%), surgery (68.4%) and radiotherapy (57.9%). Their one-year survival rate was estimated as 77.8% (95%confidence interval (CI): 58.6-97.0%).

Conclusions: We discuss the risk of breast cancer in infected patients, and the importance of taking into account the different contributing factors for breast cancer in HIV-infected individuals.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Alcohol Drinking / epidemiology
  • Anti-HIV Agents / pharmacokinetics
  • Anti-HIV Agents / therapeutic use
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / epidemiology*
  • Breast Neoplasms / radiotherapy
  • Breast Neoplasms / surgery
  • Breast Neoplasms, Male / epidemiology
  • Breast Neoplasms, Male / therapy
  • CD4 Lymphocyte Count
  • Carcinoma, Ductal, Breast / drug therapy
  • Carcinoma, Ductal, Breast / epidemiology
  • Carcinoma, Ductal, Breast / radiotherapy
  • Carcinoma, Ductal, Breast / surgery
  • Combined Modality Therapy
  • Cross-Sectional Studies
  • Drug Interactions
  • Estrogens
  • Female
  • France / epidemiology
  • HIV Infections / drug therapy
  • HIV Infections / epidemiology*
  • Humans
  • Immunocompromised Host
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Multicenter Studies as Topic / statistics & numerical data
  • Neoplasms, Hormone-Dependent / drug therapy
  • Neoplasms, Hormone-Dependent / epidemiology
  • Neoplasms, Hormone-Dependent / radiotherapy
  • Neoplasms, Hormone-Dependent / surgery
  • Progesterone
  • Prospective Studies
  • Risk Factors
  • Smoking / epidemiology
  • Surveys and Questionnaires
  • Survival Rate
  • Tumor Burden
  • Viral Load

Substances

  • Anti-HIV Agents
  • Antineoplastic Agents
  • Estrogens
  • Progesterone